<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01559090</url>
  </required_header>
  <id_info>
    <org_study_id>D3461C00002</org_study_id>
    <nct_id>NCT01559090</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of Intravenous Dose of MEDI-546 in Japanese Subjects With Systemic Lupus Erythematosus</brief_title>
  <official_title>A Phase 2, Multicenter, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of Intravenous Dose of MEDI-546, a Human Monoclonal Antibody Directed Against Type I Interferon Receptor (IFNAR), in Japanese Subjects With Active Systemic Lupus Erythematosus (SLE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess safety, tolerability, pharmacokinetics and
      pharmacodynamics of MEDI-546 in Japanese SLE patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase 2, multicenter, open-label, dose-escalation study to evaluate the safety and
      tolerability of intravenous dose of MEDI-546, a human monoclonal antibody directed against
      type I interferon receptor (IFNAR), in Japanese subjects with active systemic lupus
      erythematosus (SLE)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 20, 2012</start_date>
  <completion_date type="Actual">February 21, 2017</completion_date>
  <primary_completion_date type="Actual">August 19, 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Description of the safety profile for MEDI-546 in terms of adverse events, vital signs (body temperature, blood pressure, pulse rate and respiratory rate) and clinical laboratory assessments and electrocardiograms.</measure>
    <time_frame>From baseline up to Day 422 at Stage I, From baseline up to Day 1178 at Stage II</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Description of the PK profile for MEDI-546 in terms of peak plasma concentration (Cmax), time to peak concentration (tmax), area under concentration curve (AUC) and terminal phase half-life (t1/2)</measure>
    <time_frame>Stage I: predose/30 min post dose of Day1 and 337, predose of Day2, 8, 15, 22, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 338, 344, 351, 365, 393 and 422. Stage II: predose of Day1, 85, 169, 253, 337, 505, 673, 841, 1009, 1093, 1121 and 1178</time_frame>
    <description>Stage I: at predose and at 30 min post dose of Day 1 and 337, at predose of Days 2, 8, 15, 22, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 338, 344, 351, 365, 393 and 422. Stage II: at predose of Day 1, 85, 169, 253, 337, 505, 673, 841, 1009, 1093, 1121 and 1178</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the pharmacodynamics of MEDI-546 by assessing the impact on the type I interferon gene signature score.</measure>
    <time_frame>Stage I: Day1, 29, 85, 141, 169, 253, 337, 365, 393 and 422. Stage II: Day1, 85, 169, 253, 337, 505, 673, 841, 1009, 1093, 1121 and 1178</time_frame>
    <description>Stage I: Day1, 29, 85, 141, 169, 253, 337, 365, 393 and 422. Stage II: Day1, 85, 169, 253, 337, 505, 673, 841, 1009, 1093, 1121 and 1178</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Anti-drug antibody by assessing the number and percentage of patients developing detectable anti-MEDI-546 antibodies.</measure>
    <time_frame>Stage I: Day1, 85, 141, 169, 253, 337, 365, 393 and 422. Stage II: Day1, 85, 169, 253, 337, 505, 673, 841, 1009, 1093, 1121 and 1178</time_frame>
    <description>Stage I: Day1, 85, 141, 169, 253, 337, 365, 393 and 422. Stage II: Day1, 85, 169, 253, 337, 505, 673, 841, 1009, 1093, 1121 and 1178</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI-546 100 mg IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI-546 300 mg IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI-546 1000 mg IV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-546</intervention_name>
    <description>Stage I: 100 mg IV, single dose and multiple doses once every 4 wks for 48 wks Stage II: 300 mg IV, multiple doses once every 4 wks for 156 wks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-546</intervention_name>
    <description>Stage I: 300 mg IV, single dose and multiple doses once every 4 wks for 48 wks Stage II: 300 mg IV, multiple doses once every 4 wks for 156 wks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-546</intervention_name>
    <description>Stage I: 1000 mg IV, single dose and multiple doses once every 4 wks for 48 wks Stage II: 1000 mg IV, multiple doses once every 4 wks for 156 wks, the dose at Stage II was changed to 300 mg IV.</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fulfils at least 4 of the 11 American College of Rheumatology (ACR) classification
             criteria for SLE.

          -  Weight greater than or equal to 40.0 kg.

          -  Diagnosis of pediatric or adult SLE with chronic disease activity requiring ongoing
             treatment or observation for â‰¥ 24 weeks prior to screening.

          -  Currently receiving stable dose of oral prednisone and/or
             antimalarials/immunosuppressives.

          -  Active moderate to severe SLE disease based on SLE disease activity score.

        Exclusion Criteria:

          -  Active severe or unstable neuropsychiatric SLE.

          -  Active severe SLE-driven renal disease or unstable renal disease.

          -  Clinically significant active infection including ongoing and chronic infections.

          -  Known history of a primary immunodeficiency or an underlying condition such as human
             immunodeficiency virus infection or splenectomy that predisposes the subject to
             infection.

          -  Confirmed positive tests for hepatitis B or positive test for hepatitis C.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberta Weiss, MD</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chiba-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chuo-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ota-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sendai-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shimotsuke-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2012</study_first_submitted>
  <study_first_submitted_qc>March 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2012</study_first_posted>
  <last_update_submitted>March 7, 2017</last_update_submitted>
  <last_update_submitted_qc>March 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Japan</keyword>
  <keyword>Phase2</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Systemic Lupus Erythematosus</keyword>
  <keyword>SLE, MEDI-546</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>February 6, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

